Ikarian Capital, LLC Biogen Inc. Call Options Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $17.3 Million - $21.1 Million	-68,700 Reduced 97.45%	1,800 $498,000
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $8.12 Million - $11.2 Million	-41,700 Reduced 37.17%	70,500 $18.8 Million
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $10.7 Million - $13.5 Million	-55,300 Reduced 33.01%	112,200 $23.6 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $29 Million - $37.8 Million	-102,500 Reduced 37.96%	167,500 $47.4 Million
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $32.3 Million - $51.8 Million	-124,900 Reduced 31.63%	270,000 $93.5 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $18.3 Million - $21.5 Million	-75,500 Reduced 16.05%	394,900 $110 Million
Q4 2020 Feb 12, 2021	BUY	$236.26 - $355.63 $87.5 Million - $132 Million	370,400 Added 370.4%	470,400 $115 Million
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $11.5 Million - $13.3 Million	-43,400 Reduced 30.26%	100,000 $28.4 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $38.6 Million - $48.9 Million	143,400 New	143,400 $45.4 Million

990

131M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.